Diaphragmatic paralysis: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}} {{AE}} Your Name {{SK}} Synonym 1; Synonym 2; Synonym 3 ==Overview== Most pati...")
 
No edit summary
Line 21: Line 21:
   
   
==Pathophysiology==
==Pathophysiology==
* Diaphrgm is one of the most inspiratory muscle. <ref name="pmid7050712">{{cite journal |vauthors=Roussos C, Macklem PT |title=The respiratory muscles |journal=N. Engl. J. Med. |volume=307 |issue=13 |pages=786–97 |year=1982 |pmid=7050712 |doi=10.1056/NEJM198209233071304 |url=}}</ref>
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.

Revision as of 20:42, 8 February 2018

WikiDoc Resources for Diaphragmatic paralysis

Articles

Most recent articles on Diaphragmatic paralysis

Most cited articles on Diaphragmatic paralysis

Review articles on Diaphragmatic paralysis

Articles on Diaphragmatic paralysis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Diaphragmatic paralysis

Images of Diaphragmatic paralysis

Photos of Diaphragmatic paralysis

Podcasts & MP3s on Diaphragmatic paralysis

Videos on Diaphragmatic paralysis

Evidence Based Medicine

Cochrane Collaboration on Diaphragmatic paralysis

Bandolier on Diaphragmatic paralysis

TRIP on Diaphragmatic paralysis

Clinical Trials

Ongoing Trials on Diaphragmatic paralysis at Clinical Trials.gov

Trial results on Diaphragmatic paralysis

Clinical Trials on Diaphragmatic paralysis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Diaphragmatic paralysis

NICE Guidance on Diaphragmatic paralysis

NHS PRODIGY Guidance

FDA on Diaphragmatic paralysis

CDC on Diaphragmatic paralysis

Books

Books on Diaphragmatic paralysis

News

Diaphragmatic paralysis in the news

Be alerted to news on Diaphragmatic paralysis

News trends on Diaphragmatic paralysis

Commentary

Blogs on Diaphragmatic paralysis

Definitions

Definitions of Diaphragmatic paralysis

Patient Resources / Community

Patient resources on Diaphragmatic paralysis

Discussion groups on Diaphragmatic paralysis

Patient Handouts on Diaphragmatic paralysis

Directions to Hospitals Treating Diaphragmatic paralysis

Risk calculators and risk factors for Diaphragmatic paralysis

Healthcare Provider Resources

Symptoms of Diaphragmatic paralysis

Causes & Risk Factors for Diaphragmatic paralysis

Diagnostic studies for Diaphragmatic paralysis

Treatment of Diaphragmatic paralysis

Continuing Medical Education (CME)

CME Programs on Diaphragmatic paralysis

International

Diaphragmatic paralysis en Espanol

Diaphragmatic paralysis en Francais

Business

Diaphragmatic paralysis in the Marketplace

Patents on Diaphragmatic paralysis

Experimental / Informatics

List of terms related to Diaphragmatic paralysis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Most patients with unilateral diaphragmatic paralysis are asymptomatic and do not require treatment

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • Diaphrgm is one of the most inspiratory muscle. [1]
  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

  1. Roussos C, Macklem PT (1982). "The respiratory muscles". N. Engl. J. Med. 307 (13): 786–97. doi:10.1056/NEJM198209233071304. PMID 7050712.